Longevity field hails ‘landmark step’ as US
Author: Michael
Targeting toxic fibrin deposits, startup seeks t
New data suggests treatment with Wegovy offers ‘remarkable’ cardioprotective effects – before significant weight loss occurs. This week, Danish pharma giant Novo Nordisk announced new data highlighting the early cardiovascular benefits of Wegovy at the European Congress of Obesity. The company presented a secondary analysis from the Phase 3 SELECT trial, which revealed that Wegovy reduced the risk of major adverse cardiovascular events – including cardiovascular death and non-fatal heart attacks – by 37% compared with placebo within the first three months of treatment. Within six months, the risk of death from cardiovascular disease was halved, and the likelihood of…
As the clinical phase begins, Peter Diamandis ou
Petro Trush on turning wartime biotech into peac
New report reveals $8.
Non-profit pours grant funding into research foc
Startup lands $65m and targets clinical trials o
Global competition enters clinical phase as sele
Drug based on naturally occurring protective ant